Marshall Wace, LLP Uro Gen Pharma Ltd. Transaction History

Marshall Wace, LLP

$72.2 Billion
Q2 2024

A detailed history of Marshall Wace, LLP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Marshall Wace, LLP holds 42,841 shares of URGN stock, worth $530,371. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,841

Holding current value

$530,371

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $544,937 - $822,547	42,841 New	42,841 $718,000
Q4 2023 Feb 14, 2024	BUY	$10.87 - $15.93 $18,815 - $27,574	1,731 Added 6.45%	28,552 $428,000
Q3 2023 Nov 14, 2023	SELL	$8.84 - $22.64 $530,921 - $1.36 Million	-60,059 Reduced 69.13%	26,821 $375,000
Q2 2023 Aug 14, 2023	BUY	$8.75 - $14.29 $626,255 - $1.02 Million	71,572 Added 467.55%	86,880 $899,000
Q1 2023 May 15, 2023	BUY	$7.99 - $11.02 $122,310 - $168,694	15,308 New	15,308 $141,000
Q1 2020 May 15, 2020	SELL	$13.68 - $34.6 $24,199 - $61,207	-1,769 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$21.11 - $34.86 $11,610 - $19,173	550 Added 45.12%	1,769 $59,000
Q3 2019 Nov 14, 2019	BUY	$23.83 - $36.44 $29,048 - $44,420	1,219 New	1,219 $29,000

Others Institutions Holding URGN

# of Institutions

120

Shares Held

39.3M

Call Options Held

158K

Put Options Held

161K

Rtw Investments, LP New York, NY

3.56M
Shares

$44 Million
1.0% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

3.3M
Shares

$40.9 Million
0.11% of portfolio
Ra Capital Management, L.P. Boston, MA

3.08M
Shares

$38.2 Million
0.78% of portfolio
Great Point Partners LLC Greenwich, CT

2.91M
Shares

$36 Million
12.93% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

2.45M
Shares

$30.3 Million
0.11% of portfolio

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $282M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account